In case of research misconduct in a CTN trial, which of the following is INCORRECT:
A. The research integrity officer must be contacted immediately when an allegation of research misconduct is made.
B. The research integrity officer should alert the NIDA Center for the Clinical Trials Network office that an allegation of research misconduct has been made.
C. Within NIDA, responsibility for oversight of inquiries and investigations into research misconduct rests with the Office of Extramural Affairs.
D. NIDA must inform the FDA of all research misconduct allegations.
E. All are correct.
E. All of the above.